Skip to Main Content

Paper Details

Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer.
Int J Radiat Oncol Biol Phys
7
2023
Cancer, Non-Small Cell Lung
Author NameAffiliation
Tahmineh RomeroUniversity of California los angeles
Jonathan W GoldmanUniversity of California los angeles
Jonathan W GoldmanUniversity of California los angeles
Edward B GaronUniversity of California los angeles
Edward B GaronUniversity of California los angeles
Aaron LisbergUniversity of California los angeles
Aaron LisbergUniversity of California los angeles
Benjamin SolomonPeter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne
Michael L SteinbergUniversity of California los angeles
  • 1 - 9

Datasets

Release 1.2